{"id":"meningococcal-conjugate-vaccine-gsk134612","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meningococcal conjugate vaccines work by conjugating polysaccharide antigens from the meningococcal capsule to a protein carrier, which enhances T-cell dependent immune responses and improves immunogenicity compared to unconjugated polysaccharide vaccines. This approach generates both antibody and cellular immunity, providing protection against invasive meningococcal disease caused by the targeted serogroups. GSK134612 is designed to provide broad coverage against multiple meningococcal serogroups.","oneSentence":"This conjugate vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide capsules by linking them to a protein carrier.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:45.161Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease"}]},"trialDetails":[{"nctId":"NCT01939158","phase":"PHASE3","title":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-02","conditions":"Infections, Meningococcal","enrollment":803},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT01266993","phase":"PHASE3","title":"Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-03","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":271},{"nctId":"NCT00474266","phase":"PHASE3","title":"Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-05","conditions":"Infections, Meningococcal","enrollment":1000},{"nctId":"NCT00674583","phase":"PHASE3","title":"Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-09","conditions":"Infections, Meningococcal","enrollment":414},{"nctId":"NCT01934140","phase":"PHASE3","title":"Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-04","conditions":"Infections, Meningococcal","enrollment":311},{"nctId":"NCT01340898","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-27","conditions":"Meningococcal Infection","enrollment":753},{"nctId":"NCT00718666","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-20","conditions":"Infections, Meningococcal","enrollment":387},{"nctId":"NCT00471081","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-05","conditions":"Infections, Meningococcal","enrollment":385},{"nctId":"NCT01962207","phase":"PHASE3","title":"The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Infections, Meningococcal","enrollment":243},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156},{"nctId":"NCT00496015","phase":"PHASE3","title":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Streptococcal","enrollment":750},{"nctId":"NCT00661557","phase":"PHASE2","title":"Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05-19","conditions":"Infections, Meningococcal","enrollment":271},{"nctId":"NCT01154088","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-27","conditions":"Infections, Meningococcal","enrollment":1170},{"nctId":"NCT00453986","phase":"PHASE3","title":"Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-09","conditions":"Infections, Meningococcal","enrollment":1352},{"nctId":"NCT00614614","phase":"PHASE3","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-13","conditions":"Infections, Meningococcal","enrollment":1558},{"nctId":"NCT01235975","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-30","conditions":"Infections, Meningococcal","enrollment":400},{"nctId":"NCT01755689","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-11","conditions":"Infections, Meningococcal","enrollment":1300},{"nctId":"NCT01165242","phase":"PHASE2","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-19","conditions":"Infections, Meningococcal","enrollment":1013},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461},{"nctId":"NCT01641042","phase":"PHASE3","title":"Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-10","conditions":"Infections, Meningococcal","enrollment":86},{"nctId":"NCT01767376","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-10","conditions":"Infections, Meningococcal","enrollment":692},{"nctId":"NCT00715910","phase":"PHASE2","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Infections, Meningococcal","enrollment":818}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Meningococcal conjugate vaccine GSK134612","genericName":"Meningococcal conjugate vaccine GSK134612","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This conjugate vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide capsules by linking them to a protein carrier. Used for Prevention of invasive meningococcal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}